Xilio Therapeutics (XLO) Shares Outstanding (Weighted Average) (2020 - 2026)

Xilio Therapeutics has disclosed Shares Outstanding (Weighted Average) across 7 years of filings, most recently posting $16.3 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $16.3 million, down 36.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.3 million (down 36.15% YoY), and the FY2025 annual result was $4.2 million, up 10.89% from the prior year.
• Shares Outstanding (Weighted Average) came in at $16.3 million for Q1 2026 at Xilio Therapeutics, up from $4.2 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $92.3 million in Q2 2025 to a low of $3.8 million in Q4 2024.
• The 5-year median for Shares Outstanding (Weighted Average) is $27.4 million (2022), against an average of $32.0 million.
• Across the five-year window, Shares Outstanding (Weighted Average) surged 3764.01% in 2022 and tumbled 86.1% in 2024, its largest moves.
• Xilio Therapeutics' Shares Outstanding (Weighted Average) stood at $27.4 million in 2022, then advanced by 0.38% to $27.5 million in 2023, then sank by 86.1% to $3.8 million in 2024, then gained by 10.89% to $4.2 million in 2025, then surged by 285.69% to $16.3 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $16.3 million (Q1 2026), $4.2 million (Q4 2025), and $92.3 million (Q3 2025), per Business Quant data.